Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Deals

GenScript ProBio Partners with Bio Immunitas for hRPP Platform

Fineline Cube Feb 9, 2023

Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a...

Company Drug

ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment

Fineline Cube Feb 9, 2023

Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011...

Company Deals

Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs

Fineline Cube Feb 9, 2023

China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...

Company Deals

Neurodawn Completes Series A+ Financing for CNS Drug Development

Fineline Cube Feb 9, 2023

Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has...

Company Drug

Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study

Fineline Cube Feb 9, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment...

Company Deals

Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering

Fineline Cube Feb 9, 2023

Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional...

Company Deals

Teddy Clinical Research Lab Partners with Cerba Research for Global Services

Fineline Cube Feb 9, 2023

China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244)...

Company Deals

Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma

Fineline Cube Feb 8, 2023

Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...

Company Deals

Macrolux Secures Series A Funding for Endoscopy Solutions

Fineline Cube Feb 8, 2023

Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB...

Company Deals

Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin

Fineline Cube Feb 8, 2023

China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...

Company Drug

SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza

Fineline Cube Feb 8, 2023

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...

Company Deals

Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs

Fineline Cube Feb 8, 2023

Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a...

Company Deals

Beijing Smart Beam Raises Series A+ Funding for CT X-Ray Tube Development

Fineline Cube Feb 8, 2023

Beijing Smart Beam Technology, a leading vacuum electronic device maker, has reportedly raised “tens of...

Company Deals

Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research

Fineline Cube Feb 8, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a...

Company

Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact

Fineline Cube Feb 7, 2023

Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial...

Company

Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth

Fineline Cube Feb 7, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its...

Company Drug

Fujian Cosunter’s HBV Therapy GST-HG141 Begins Phase II Trial

Fineline Cube Feb 7, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the first patient enrollment and...

Company Drug

Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study

Fineline Cube Feb 7, 2023

US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...

Company Deals

Lifetech Partners with Jenscare for Structural Heart Disease Devices

Fineline Cube Feb 7, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare...

Posts pagination

1 … 604 605 606 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.